TNXP TONIX PHARMACEUTICALS HLDG C revenue, earnings and financials

For the quarter ended June 30, 2026, TONIX PHARMACEUTICALS HLDG C reported revenue of $13.5M (up 577.9% from a year earlier), net income of −$40.6M and diluted EPS of −$2.44; over the last four quarters revenue was $29.1M and net income −$160M; for the fiscal year ended December 2025 revenue was $13.1M, up 29.8% on the year before.

TNXP annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $13.1M, gross profit n/a, operating income −$126M, net income −$124M (margin -946.2%), EPS −$14.57
• Fiscal year ended Dec 2024: revenue $10.1M, gross profit n/a, operating income −$137M, net income −$130M (margin -1288.3%), EPS −$176.60
• Fiscal year ended Dec 2023: revenue $7.77M, gross profit n/a, operating income −$118M, net income −$117M (margin -1501.8%), EPS −$14720.25
• Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$112M, net income −$110M (margin n/a), EPS −$20.01
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$92.3M, net income −$92.3M (margin n/a), EPS −$8.10

TNXP quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $13.5M (up 577.9% year over year), net income −$40.6M, EPS −$2.44
• Quarter ended Mar 31, 2026: revenue $6.88M (up 183.2% year over year), net income −$40.2M, EPS −$2.93
• Quarter ended Dec 31, 2025 (from the annual report): revenue $5.39M (up 108.8% year over year), net income −$46.9M, EPS −$4.28
• Quarter ended Sep 30, 2025: revenue $3.29M (up 16.6% year over year), net income −$32.0M, EPS −$3.59
• Quarter ended Jun 30, 2025: revenue $2.00M (down 9.5% year over year), net income −$28.3M, EPS −$3.86
• Quarter ended Mar 31, 2025: revenue $2.43M (down 2.1% year over year), net income −$16.8M, EPS −$2.84
• Quarter ended Dec 31, 2024 (from the annual report): revenue $2.58M, net income −$22.1M, EPS $2302.65
• Quarter ended Sep 30, 2024: revenue $2.82M (down 29.3% year over year), net income −$14.2M, EPS −$22.68
• Quarter ended Jun 30, 2024: revenue $2.21M, net income −$78.8M, EPS −$1920.85
• Quarter ended Mar 31, 2024: revenue $2.48M, net income −$14.9M, EPS −$535.72
• Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$27.3M, EPS −$14629.18
• Quarter ended Sep 30, 2023: revenue $3.99M, net income −$28.0M, EPS −$38.63
• Quarter ended Jun 30, 2023: revenue n/a, net income −$28.4M, EPS −$49.23
• Quarter ended Mar 31, 2023: revenue n/a, net income −$33.0M, EPS −$3.21
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$31.7M, EPS −$6.52
• Quarter ended Sep 30, 2022: revenue n/a, net income −$29.0M, EPS −$4.24
• Quarter ended Jun 30, 2022: revenue n/a, net income −$23.1M, EPS −$7.64
• Quarter ended Mar 31, 2022: revenue n/a, net income −$26.4M, EPS −$1.61
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$29.6M, EPS −$4.18
• Quarter ended Sep 30, 2021: revenue n/a, net income −$18.5M, EPS −$1.60

TNXP cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$99.8M, share buybacks $13.8M
• Fiscal year ended Dec 2024: operating cash flow −$60.9M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$102M, share buybacks $14.0M
• Fiscal year ended Dec 2022: operating cash flow −$98.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$75.6M, share buybacks n/a

TNXP balance sheet

• Jun 30, 2026: cash $176M, total assets $254M, total liabilities $31.8M, shareholders' equity $222M
• Mar 31, 2026: cash $185M, total assets $258M, total liabilities $30.8M, shareholders' equity $227M
• Dec 31, 2025: cash $208M, total assets $277M, total liabilities $32.0M, shareholders' equity $245M
• Sep 30, 2025: cash $190M, total assets $252M, total liabilities $21.3M, shareholders' equity $231M
• Jun 30, 2025: cash $125M, total assets $187M, total liabilities $19.4M, shareholders' equity $168M
• Mar 31, 2025: cash $132M, total assets $193M, total liabilities $12.5M, shareholders' equity $180M
• Dec 31, 2024: cash $98.8M, total assets $163M, total liabilities $23.3M, shareholders' equity $140M, long-term debt $4.67M
• Sep 30, 2024: cash $28.2M, total assets $95.0M, total liabilities $20.8M, shareholders' equity $74.2M, long-term debt $5.17M

What is TNXP's revenue?

TONIX PHARMACEUTICALS HLDG C reported $29.1M of revenue over its last four quarters, through June 30, 2026.

Is TNXP profitable?

No. TONIX PHARMACEUTICALS HLDG C lost $160M over the last four quarters.

What is TNXP's EPS?

Diluted earnings per share over the last four quarters were −$13.24; −$2.44 in the latest quarter.

TNXP ownership and insider trades · All stocks